abrdn Life Sciences Investors (NYSE:HQL) Short Interest Down 34.6% in December

Impact · against what's priced in

The decrease in short interest for HQL is not a material catalyst. With only 0.2% of shares short sold, there is effectively no bearish conviction to reverse, and the absolute volume of shares is too low to impact the stock price.

HQL+0.05: No priced-in read yet
In context: Short interest dropped 34.6% in December to 54,047 shares, but the remaining short interest represents a negligible 0.2% of shares.
Read from the article alone

abrdn Life Sciences Investors (NYSE:HQL) Short Interest Down 34.6% in December

biotech
HQL
life sciences
short interest

Search tags

abrdn Life Sciences Investors (NYSE:HQL) Short Interest Down 34.6% in December

What matters in this story

2 healthcare stocks to turn $10 into $100 by next year

abrdn Life Sciences Investors (NYSE:HQL) Short Interest Down 34.6% in December

What matters in this story

2 healthcare stocks to turn $10 into $100 by next year

How each ticker is affected

Track these names every morning.

TransMedics: 2027 Setting Up To Be A Pivotal Year

New Phase 3b data on Lilly's Taltz (ixekizumab) and Zepbound (tirzepatide) used together showed improved and durable efficacy, patient-reported and metabolic outcomes at one year in adults with psoriatic arthritis and obesity

AstraZeneca's Oncology Growth Is Outrunning The Farxiga Decline

Akari Therapeutics Participates in Virtual Investor “What This Means” Segment Featuring Newly Appointed Chief Business Officer Vatnak Vat-Ho

abrdn Life Sciences Investors (NYSE:HQL) Short Interest Down 34.6% in December

What matters in this story

Next reads from the same story arc

2 healthcare stocks to turn $10 into $100 by next year

abrdn Life Sciences Investors (NYSE:HQL) Short Interest Down 34.6% in December

What matters in this story

Next reads from the same story arc

2 healthcare stocks to turn $10 into $100 by next year

How each ticker is affected

Track these names every morning.

TransMedics: 2027 Setting Up To Be A Pivotal Year

New Phase 3b data on Lilly's Taltz (ixekizumab) and Zepbound (tirzepatide) used together showed improved and durable efficacy, patient-reported and metabolic outcomes at one year in adults with psoriatic arthritis and obesity

AstraZeneca's Oncology Growth Is Outrunning The Farxiga Decline

Akari Therapeutics Participates in Virtual Investor “What This Means” Segment Featuring Newly Appointed Chief Business Officer Vatnak Vat-Ho